Valuation, from the filing
| Public float | $111.00M | Market value of stock held by non-affiliates, as stated on the cover page for 2025-06-30 |
|---|---|---|
| Float per share | $1.74 | Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself. |
| Float / equity | 5.3× | A lower bound on the multiple, because affiliate holdings are excluded. |
Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.
How this compares in its industry
Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.
| Measure | Reported | Percentile | |
|---|---|---|---|
| Current ratio | 0.78x | 13th |
TuHURA Biosciences, Inc./NV (HURA) reported revenue of $0 and net income of -$30.05M for the fiscal year ended 2025-12-31. This page shows 3 annual periods of income statement, balance sheet and cash flow figures normalized from TuHURA Biosciences, Inc./NV’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.
Income
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of revenue | Unavailable | Unavailable | Unavailable |
| Gross profit | Unavailable | Unavailable | Unavailable |
| Operating income | Unavailable | Unavailable | Unavailable |
| Net income | -$30.05M | -$21.68M | -$29.32M |
| Research & development | $20.53M | $13.34M | $9.40M |
| Weighted-average diluted shares | shares 47.93M | shares 18.66M | shares 11.89M |
| Pretax income | -$30.05M | -$21.68M | $29.30M |
| Income tax expense | $1.60K | $3.77K | $0 |
| Diluted EPS | $-0.63 | $-1.21 | $-2.47 |
| Selling, general & administrative | Unavailable | Unavailable | Unavailable |
| General & administrative | $7.58M | $3.87M | $4.14M |
| Selling & marketing | Unavailable | Unavailable | Unavailable |
Balance
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash & equivalents | $3.62M | $12.66M | $3.67M |
| Total assets | $27.35M | $19.97M | $4.36M |
| Current assets | $4.62M | $19.61M | $4.16M |
| Total liabilities | $6.42M | $5.37M | $5.92M |
| Current liabilities | $5.92M | $5.33M | $3.60M |
| Total equity incl. NCI | $20.93M | $14.59M | -$1.56M |
| Temporary (mezzanine) equity | Unavailable | Unavailable | Unavailable |
| Inventory | Unavailable | Unavailable | Unavailable |
| Accounts receivable | Unavailable | Unavailable | Unavailable |
| Goodwill | $10.74M | Unavailable | Unavailable |
| Long-term debt | Unavailable | Unavailable | Unavailable |
| Accounts payable | $3.77M | $3.15M | $1.87M |
Cash flow
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating cash flow | -$27.63M | -$14.73M | -$11.95M |
| Capital expenditures | $76.08K | $57.91K | $79.22K |
| Investing cash flow | -$1.34M | -$6.05M | -$1.30M |
| Financing cash flow | $19.93M | $29.77M | $2.66M |
| Net change in cash | -$9.04M | $8.99M | -$10.59M |
| Stock-based compensation | $6.42M | $1.96M | $478.89K |
| Common dividends paid | Unavailable | Unavailable | Unavailable |
| Common share repurchases | Unavailable | Unavailable | $24.75K |
| Depreciation & amortization | $71.26K | $116.71K | $177.38K |
Derived
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Free cash flow | -$27.71M | -$14.79M | -$12.03M |
| Gross margin | Unavailable | Unavailable | Unavailable |
| Operating margin | Unavailable | Unavailable | Unavailable |
| FCF margin | Unavailable | Unavailable | Unavailable |
| SBC / revenue | Unavailable | Unavailable | Unavailable |
| Current ratio | 0.78x | 3.68x | 1.16x |
| Revenue YoY growth | Unavailable | Unavailable | Unavailable |
| Net margin | Unavailable | Unavailable | Unavailable |
| R&D / revenue | Unavailable | Unavailable | Unavailable |
| CapEx / revenue | Unavailable | Unavailable | Unavailable |
| Long-term debt / equity | Unavailable | Unavailable | Unavailable |
| Effective tax rate | Unavailable | Unavailable | 0.0% |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open HURA in the interactive workspace to inspect any figure back to its filing.
Source filings
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.